TARS
HEALTHCARETarsus Pharmaceuticals Inc
AI Insight
What's Moving TARS Today?
No stock-specific AI insight has been generated for TARS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$38.51$85.25
$65.27
Fundamentals
Market Cap$2.7B
P/E Ratio—
EPS$-1.11
Dividend Yield—
Dividend / Share—
ROE-14.0%
Profit Margin-9.0%
Debt / Equity—
Trading
Volume860K
Avg Volume (10D)—
Shares Outstanding43.0M
TARS News
24 articles- Tarsus Pharmaceuticals Inc (TARS) Dividends & Stock Splits: Historical Payouts and Event TimelineTradingKey·Jun 18, 2026
- A Look At Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Strength And Perceived DiscountYahoo Finance·Jun 10, 2026
- TARS Financials: Revenue Breakdown, Margins & Competitor ComparisonIntellectia AI·Jun 3, 2026
- Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of DirectorsYahoo Finance·Jun 2, 2026
- Tarsus to Participate in Upcoming Investor ConferencesYahoo Finance·May 28, 2026
- This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 MillionMotley Fool·May 24, 2026
- This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last QuarterMotley Fool·May 24, 2026
- Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million AmericansYahoo Finance·May 14, 2026
- Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness And Long Term GainsYahoo Finance·May 12, 2026
- Is It Time To Reassess Tarsus Pharmaceuticals (TARS) After Its Recent Share Price Swings?Yahoo Finance·May 11, 2026
- Tarsus Pharmaceuticals (TARS) Losses Narrow In Q1 2026 Challenging Bearish NarrativesSimply Wall Street·May 8, 2026
- Earnings call transcript: Tarsus Pharmaceuticals Q1 2026 beats EPS forecast, stock dipsInvesting.com Australia·May 7, 2026
- Tarsus Pharmaceuticals Q1 Earnings Call HighlightsMarketbeat·May 7, 2026
- Tarsus Pharmaceuticals, Inc. Q1 2026 Earnings Call SummaryMoby·May 7, 2026
- Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 6, 2026
- Tarsus Reports First Quarter 2026 Financial Results and Recent Business AchievementsYahoo Finance·May 6, 2026
- Amgen (AMGN) Q1 Earnings and Revenues Beat EstimatesYahoo Finance·Apr 30, 2026
- Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026Yahoo Finance·Apr 29, 2026
- Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Moves And Ongoing LossesYahoo Finance·Apr 3, 2026
- How TP-05’s Phase 2 Lyme Prophylaxis Trial Progress Could Impact Tarsus Pharmaceuticals (TARS) InvestorsYahoo Finance·Apr 3, 2026
- Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme DiseaseYahoo Finance·Mar 31, 2026
- Tarsus Pharmaceuticals Stock Earns Upgrade To RS RatingYahoo Finance·Mar 26, 2026
- Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked TradeThe Motley Fool·Mar 24, 2026
- TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to TarsusYahoo Finance·Mar 23, 2026
All 24 articles loaded
Price Data
Open$63.88
Previous Close$63.56
Day High$66.48
Day Low$63.81
52 Week High$85.25
52 Week Low$38.51
52-Week Range
$38.51$85.25
$65.27
Fundamentals
Market Cap$2.7B
P/E Ratio—
EPS$-1.11
Dividend Yield—
Dividend / Share—
ROE-14.0%
Profit Margin-9.0%
Debt / Equity—
Trading
Volume860K
Avg Volume (10D)—
Shares Outstanding43.0M
About Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates for ophthalmic conditions. The company is headquartered in Irvine, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—